Intra-Cellular Therapies (ITCI) Earnings Date, Estimates & Call Transcripts $73.54 +1.12 (+1.55%) (As of 09/6/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Earnings SummaryUpcoming Earnings DateNov. 7EstimatedActual EPS (Aug. 7) -$0.16 Beat By $0.03 Consensus EPS (Aug. 7) -$0.19 Conference Call TranscriptConference Call AudioEarnings Press Release Get Intra-Cellular Therapies Earnings AlertsEnter your email address below to receive the latest news and earnings results for ITCI and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueITCI Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ITCI Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Porter & CompanyWhy billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. Click here for my exclusive video Intra-Cellular Therapies Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241($0.48)($0.48)($0.48)Q2 20241($0.16)($0.16)($0.16)Q3 20241($0.07)($0.07)($0.07)Q4 20241($0.06)($0.06)($0.06)FY 20244($0.77)($0.77)($0.77)ITCI Earnings Date and InformationIntra-Cellular Therapies last released its earnings data on August 7th, 2024. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.03. The company earned $161.40 million during the quarter, compared to analysts' expectations of $157.74 million. Its revenue was up 45.7% compared to the same quarter last year. Intra-Cellular Therapies has generated ($1.16) earnings per share over the last year (($1.16) diluted earnings per share). Earnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($0.59) to $0.53 per share. Intra-Cellular Therapies has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 7th, 2024 based off prior year's report dates.Read More Intra-Cellular Therapies Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 11/7/2024(Estimated)------- 8/7/2024Q2 2024($0.19)($0.16)+$0.03($0.16)$157.74 million$161.40 million 5/7/2024Q1 2024($0.31)($0.16)+$0.15($0.16)$141.41 million$144.90 million 2/22/2024Q4 2023($0.44)($0.30)+$0.14($0.30)$135.97 million$132.10 million 11/2/2023Q3 2023($0.59)($0.25)+$0.34($0.25)$118.35 million$126.17 million 8/3/2023Q2 2023($0.62)($0.45)+$0.17($0.45)$106.45 million$110.80 million 5/4/2023Q1 2023($0.63)($0.46)+$0.17($0.46)$92.14 million$95.31 million Get the Latest News and Ratings for ITCI and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter. 3/1/2023Q4 2022($0.62)($0.45)+$0.17($0.45)$86.97 million$87.87 million 11/3/2022Q3 2022($0.86)($0.57)+$0.29($0.57)$64.95 million$71.87 million 8/9/2022Q2 2022($0.79)($0.92)($0.13)($0.92)$48.62 million$55.58 million 5/10/2022Q1 2022($0.93)($0.78)+$0.15($0.78)$33.52 million$35.00 million 3/1/2022Q4 2021($1.05)($1.05)-($1.05)$24.93 million$25.67 million 11/8/2021Q3 2021($0.92)($0.95)($0.03)($0.95)$22.11 million$22.21 million 8/8/2021Q2 2021($0.79)($0.85)($0.06)($0.85)$19.04 million$20.00 million 5/9/2021Q1 2021($0.81)($0.65)+$0.16($0.65)$15.74 million$15.88 million 2/24/2021Q4 2020($0.85)($0.76)+$0.09($0.76)$12.45 million$12.45 million 11/14/2020Q3 2020($1.00)($0.79)+$0.21($0.79)$6.52 million$7.37 million 8/10/2020Q2 2020($0.94)($0.96)($0.02)($0.96)$3.05 million$1.91 million 5/7/2020Q1 2020($0.93)($0.73)+$0.20($0.73)$1.75 million$1.08 million 3/2/2020Q4 2019($0.81)($0.74)+$0.07($0.74)-$0.06 million 11/5/2019Q3 2019($0.80)($0.63)+$0.17($0.63)-- Intra-Cellular Therapies Earnings - Frequently Asked Questions When is Intra-Cellular Therapies's earnings date? Intra-Cellular Therapies has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 7th, 2024 based off last year's report dates. Learn more on ITCI's earnings history. Did Intra-Cellular Therapies beat their earnings estimates last quarter? In the previous quarter, Intra-Cellular Therapies (NASDAQ:ITCI) reported ($0.16) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.19) by $0.03. Learn more on analysts' earnings estimate vs. ITCI's actual earnings. How can I listen to Intra-Cellular Therapies's earnings conference call? The conference call for Intra-Cellular Therapies's latest earnings report can be listened to online. Listen to Conference Call How can I read Intra-Cellular Therapies's conference call transcript? The conference call transcript for Intra-Cellular Therapies's latest earnings report can be read online. Read Transcript How much revenue does Intra-Cellular Therapies generate each year? Intra-Cellular Therapies (NASDAQ:ITCI) has a recorded annual revenue of $563.44 million. How much profit does Intra-Cellular Therapies generate each year? Intra-Cellular Therapies (NASDAQ:ITCI) has a recorded net income of -$139.67 million. ITCI has generated -$1.16 earnings per share over the last four quarters. What is Intra-Cellular Therapies's EPS forecast for next year? Intra-Cellular Therapies's earnings are expected to grow from ($0.59) per share to $0.53 per share in the next year. More Earnings Resources from MarketBeat Related Companies: KURA Earnings ZYME Earnings IRWD Earnings IGMS Earnings CYRX Earnings ZNTL Earnings PRLD Earnings MRNA Earnings TEVA Earnings BNTX Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Is Merck Stock Undervalued After Its Colossal Earnings Growth?Polestar Lives to Fight Another Day After Q2 EarningsWhy NVIDIA’s Earnings Point to a Bullish Future for Pure StorageDoes A&F's Q2 Earnings Win Point to a Strong Holiday Season?Salesforce Beats Earnings, Raises Full-Year Profit OutlookDon’t Count Out CrowdStrike Yet: Key Insights from Q2 EarningsNVIDIA: Analysts Bullish Ahead of Earnings - Is It a Buy Now? This page (NASDAQ:ITCI) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intra-Cellular Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intra-Cellular Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.